Monopar Therapeutics (MNPR) Cash from Operations (2017 - 2025)

Monopar Therapeutics (MNPR) has 9 years of Cash from Operations data on file, last reported at 3370072.0 in Q4 2025.

• For the quarter ending Q4 2025, Cash from Operations fell 68.64% year-over-year to 3370072.0; the trailing twelve-month figure through Dec 2025 stood at 12201291.0 (down 90.52% YoY), and the FY2025 full-year result was 12201291.0, down 90.52% from the prior year.
• Cash from Operations retreated to 3370072.0 in Q4 2025, from 2090532.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 1073500.0 in Q3 2024 to a low of 5663316.0 in Q1 2025.
• A 5-year average of 2050484.15 and a median of 1940564.5 in 2021 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations jumped 44.66% in 2024 and slumped 242.11% in 2025, its largest moves.
• Tracing MNPR's Cash from Operations over 5 years: stood at 2031905.0 in 2021, then jumped by 35.93% to 1301806.0 in 2022, then declined by 18.75% to 1545899.0 in 2023, then slipped by 29.27% to 1998418.0 in 2024, then plunged by 68.64% to 3370072.0 in 2025.
• Business Quant data shows MNPR's Cash from Operations at 3370072.0 in Q4 2025, 2090532.0 in Q3 2025, and 1077371.0 in Q2 2025.